Life sciences venture capital major Abingworth is reportedly looking to raise up to $1.5bn in funding to be deployed for clinical development projects partnered with pharma companies in return for future royalties.
The investment group, acquired by US private equity giant Carlyle in 2022, is planning to use the fund to finance up to eight late-stage clinical...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?